Heart Disease and Food and Drug Administration

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/11/2021 Medical Societies Support Safety and Benefits of Ultrasound Contrast Agents Yahoo News ... heart disease, stratify the risk of heart attack or stroke, identify and characterize tumors throughout the abdomen, and monitor the effectiveness of cancer therapies in adults and children.All three medical societies issued statements reacting to a recent communication from the Food and Drug Administration "stakeholder engagement staff" citing 13 suspected adverse reactions to polyethylene glycol (PEG), an inactive ingredient in two UCAs, without mentioning that reactions to UCAs are ...
5/11/2021 Medical Societies Support Safety and Benefits of Ultrasound Contrast Agents Yahoo News ... heart disease, stratify the risk of heart attack or stroke, identify and characterize tumors throughout the abdomen, and monitor the effectiveness of cancer therapies in adults and children.All three medical societies issued statements reacting to a recent communication from the Food and Drug Administration "stakeholder engagement staff" citing 13 suspected adverse reactions to polyethylene glycol (PEG), an inactive ingredient in two UCAs, without mentioning that reactions to UCAs are ...
5/11/2021 Medical Societies Support Safety and Benefits of Ultrasound Contrast Agents | Business Wire Business Wire ... heart disease, stratify the risk of heart attack or stroke, identify and characterize tumors throughout the abdomen, and monitor the effectiveness of cancer therapies in adults and children.All three medical societies issued statements reacting to a recent communication from the Food and Drug Administration ‚Austakeholder engagement staff‚Au citing 13 suspected adverse reactions to polyethylene glycol (PEG), an inactive ingredient in two UCAs, without mentioning that reactions to UCAs ...
5/11/2021 The Ridgway Record ... heart disease, stratify the risk of heart attack or stroke, identify and characterize tumors throughout the abdomen, and monitor the effectiveness of cancer therapies in adults and children.All three medical societies issued statements reacting to a recent communication from the Food and Drug Administration ‚Austakeholder engagement staff‚Au citing 13 suspected adverse reactions to polyethylene glycol (PEG), an inactive ingredient in two UCAs, without mentioning that reactions to UCAs ...
5/11/2021 Medical Societies Support Safety and Benefits of Ultrasound Contrast Agents | Financial Buzz ... heart disease, stratify the risk of heart attack or stroke, identify and characterize tumors throughout the abdomen, and monitor the effectiveness of cancer therapies in adults and children.All three medical societies issued statements reacting to a recent communication from the Food and Drug Administration ‚Austakeholder engagement staff‚Au citing 13 suspected adverse reactions to polyethylene glycol (PEG), an inactive ingredient in two UCAs, without mentioning that reactions to UCAs ...
5/10/2021 ... heart disease, stratify the risk of heart attack or stroke, identify and characterize tumors throughout the abdomen, and monitor the effectiveness of cancer therapies in adults and children.All three medical societies issued statements reacting to a recent communication from the Food and Drug Administration ‚Austakeholder engagement staff‚Au citing 13 suspected adverse reactions to polyethylene glycol (PEG), an inactive ingredient in two UCAs, without mentioning that reactions to UCAs ...
5/10/2021 The American Institute of Ultrasound in Medicine ( ... heart disease, stratify the risk of heart attack or stroke, identify and characterize tumors throughout the abdomen, and monitor the effectiveness of cancer therapies in adults and children.All three medical societies issued statements reacting to a recent communication from the Food and Drug Administration ‚Austakeholder engagement staff‚Au citing 13 suspected adverse reactions to polyethylene glycol (PEG), an inactive ingredient in two UCAs, without mentioning that reactions to UCAs ...
5/3/2021 AstraZeneca's Farxiga Gets FDA Approval For Chronic Kidney Disease Yahoo News AstraZeneca ( AZN ) has received approval from the U.S. Food and Drug Administration (FDA) for its sodium-glucose cotransporter 2 inhibitor Farxiga to treat chronic kidney disease (CKD).This approval is based on the positive data from the Phase 3 trial for the drug. Chronic kidney disease is characterized by a decrease in kidney function and is associated with an increased risk of heart disease, dialysis, or the need for a ...
5/1/2021 FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes Yahoo News ... Food and Drug Administration (FDA) was based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the FDA earlier this year.CKD, a condition defined by decreased kidney function, is often associated with a heightened risk of heart disease or stroke, or the need for dialysis or kidney transplant. 1-3 CKD is expected to become the fifth leading cause of ...
5/1/2021 FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes Yahoo News ... Food and Drug Administration (FDA) was based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the FDA earlier this year.CKD, a condition defined by decreased kidney function, is often associated with a heightened risk of heart disease or stroke, or the need for dialysis or kidney transplant. 1-3 CKD is expected to become the fifth leading cause of ...
5/1/2021 FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes | Business Wire Business Wire ... Food and Drug Administration (FDA) was based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the FDA earlier this year.CKD, a condition defined by decreased kidney function, is often associated with a heightened risk of heart disease or stroke, or the need for dialysis or kidney transplant. 1-3 CKD is expected to become the fifth leading cause of ...
5/1/2021 The Ridgway Record ... Food and Drug Administration (FDA) was based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the FDA earlier this year.CKD, a condition defined by decreased kidney function, is often associated with a heightened risk of heart disease or stroke, or the need for dialysis or kidney transplant. 1-3 CKD is expected to become the fifth leading cause of ...
5/1/2021 FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes | Financial Buzz ... Food and Drug Administration (FDA) was based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the FDA earlier this year.CKD, a condition defined by decreased kidney function, is often associated with a heightened risk of heart disease or stroke, or the need for dialysis or kidney transplant. 1-3 CKD is expected to become the fifth leading cause of ...
5/1/2021 Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes ... Food and Drug Administration (FDA) was based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the FDA earlier this year.CKD, a condition defined by decreased kidney function, is often associated with a heightened risk of heart disease or stroke, or the need for dialysis or kidney transplant. 1-3 CKD is expected to become the fifth leading cause of ...
4/30/2021 ... Food and Drug Administration (FDA) was based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the FDA earlier this year.CKD, a condition defined by decreased kidney function, is often associated with a heightened risk of heart disease or stroke, or the need for dialysis or kidney transplant. 1-3 CKD is expected to become the fifth leading cause of ...
4/30/2021 AstraZeneca's FARXIGA ® (dapagliflozin), a sodium- ... Food and Drug Administration (FDA) was based on positive results from the DAPA-CKD Phase III trial. The decision follows the Priority Review designation granted by the FDA earlier this year.CKD, a condition defined by decreased kidney function, is often associated with a heightened risk of heart disease or stroke, or the need for dialysis or kidney transplant. 1-3 CKD is expected to become the fifth leading cause of ...
4/24/2021 Medical Society Urges Use of Ultrasound Contrast Agents and Supports Safety Record | Financial Buzz ... decades,‚Au according to a statement issued Friday by ICUS, a grassroots medical society with members in 60 countries.The Food and Drug Administration Thursday announced that UCAs (sometimes also known as ‚Auultrasound enhancing agents ... agents that often improve a physician‚Aos ability to detect heart disease, stratify a patient‚Aos risk of heart attack or stroke, and help identify, characterize and stage tumors of the liver, kidney, prostate, breast ...
4/23/2021 The International Contrast Ultrasound Society (ICU ... decades,‚Au according to a statement issued Friday by ICUS, a grassroots medical society with members in 60 countries.The Food and Drug Administration Thursday announced that UCAs (sometimes also known as ‚Auultrasound enhancing agents ... agents that often improve a physician‚Aos ability to detect heart disease, stratify a patient‚Aos risk of heart attack or stroke, and help identify, characterize and stage tumors of the liver, kidney, prostate, breast ...
4/23/2021 Medical Society Urges Use of Ultrasound Contrast Agents and Supports Safety Record | Business Wire Business Wire ... decades,‚Au according to a statement issued Friday by ICUS, a grassroots medical society with members in 60 countries.The Food and Drug Administration Thursday announced that UCAs (sometimes also known as ‚Auultrasound enhancing agents ... agents that often improve a physician‚Aos ability to detect heart disease, stratify a patient‚Aos risk of heart attack or stroke, and help identify, characterize and stage tumors of the liver, kidney, prostate, breast ...
4/23/2021 ... decades,‚Au according to a statement issued Friday by ICUS, a grassroots medical society with members in 60 countries.The Food and Drug Administration Thursday announced that UCAs (sometimes also known as ‚Auultrasound enhancing agents ... agents that often improve a physician‚Aos ability to detect heart disease, stratify a patient‚Aos risk of heart attack or stroke, and help identify, characterize and stage tumors of the liver, kidney, prostate, breast ...
4/18/2021 FDA proposes slashing sodium in prepared foods CBS News Watch CBSN Live FDA proposes slashing sodium in prepared foods The Food and Drug Administration is calling on food companies to lower sodium levels in packaged and restaurant meals. The move is aimed at preventing thousands of deaths every year from heart disease and stroke. Americans currently take in nearly 50 percent more than the recommended daily limit of sodium. CBS News medical contributor and cardiologist Dr. Tara Narula joins ...
4/18/2021 FDA proposes slashing sodium in prepared foods Web Extra: Hillary Clinton discusses the cooperation with her staffers in her email investigation FDA proposes slashing sodium in prepared foodsThe Food and Drug Administration is calling on food companies to lower sodium levels in packaged and restaurant meals. The move is aimed at preventing thousands of deaths every year from heart disease and stroke. Americans currently take in nearly 50 percent more than the recommended daily limit of ...
4/12/2021 Zoll Medical Corporation acquires Respicardia, Inc. ... Food and Drug Administration (FDA) to treat moderate to severe CSA in adult patients with reduced cardiac function.According to the company, CSA results in shallow or disrupted breathing during sleep, and many patients with CSA also have heart disease, especially heart failure. Within this population, patients with CSA are at increased risk for hospitalizations and even death.ZOLL, which has been a significant investor in Respicardia for more than ...
4/12/2021 ZOLL Medical Corporation Acquires Respicardia, Inc. ... Food and Drug Administration (FDA) to treat moderate to severe CSA in adult patients with reduced cardiac function. 1 CSA results in shallow or disrupted breathing during sleep, and many patients with CSA also have heart disease, especially heart failure. 2 Within this population, patients with CSA are at increased risk for hospitalizations and even death. 3,4‚AuZOLL and Respicardia both develop innovative therapies for conditions with large unmet clinical ...
4/12/2021 ZOLL Medical Corporation Acquires Respicardia, Inc. | Business Wire Business Wire ... Food and Drug Administration (FDA) to treat moderate to severe CSA in adult patients with reduced cardiac function. 1 CSA results in shallow or disrupted breathing during sleep, and many patients with CSA also have heart disease, especially heart failure. 2 Within this population, patients with CSA are at increased risk for hospitalizations and even death. 3,4‚AuZOLL and Respicardia both develop innovative therapies for conditions with large unmet clinical ...